Ange

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ange

Property Description
Active Ingredients Ethinyl Estradiol, Levonorgestrel
Form Oral Tablet
Pharmacological Class Hormonal Contraceptive
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic

What Type of Medicine is Ange?

Ange is a combined sex-hormonal preparation used as an oral contraceptive designed for the prevention of pregnancy (contraception). This medication is classified pharmacologically as a Hormonal contraceptive, signifying its primary mechanism involves synthetic hormone action. This specific composition holds an established role in reproductive health. It is administered as a small oral tablet and represents a highly effective, reversible method of birth control, clinically recognized for its reliability when used consistently.


The Composition and Origin of Ange

The formulation of Ange contains two distinct active ingredients: Ethinyl Estradiol and Levonorgestrel. Ethinyl Estradiol functions as a synthetic estrogen component, while Levonorgestrel acts as a synthetic progestin (progestogen). Both active substances are synthetic derivatives of naturally occurring female sex hormones, chemically engineered to ensure consistent potency when taken orally. This specific combination is foundational to oral birth control and is primarily prescribed for women of reproductive potential seeking control over family planning. This combination product is one of the most widely studied and utilized forms of hormonal birth control, providing reliable contraceptive action through a combined hormonal input.


How Does This Combination Work to Prevent Pregnancy?

The combination of synthetic estrogen and progestin creates a powerful, layered, protective multi-mechanism action against conception. This dual hormonal input is supported by pharmacological studies and primarily functions by preventing ovulation, which stops the release of an egg from the ovary. Concurrently, the hormones cause two critical peripheral effects: thickening of cervical mucus, which physically impedes sperm movement, and subtle alteration of the uterine lining (endometrium), making the environment unfavorable for potential implantation. These actions collectively deliver the product's fundamental therapeutic objective: robust prevention of pregnancy.

Regulatory References

  1. WHO Model List of Essential Medicines: Ethinylestradiol + levonorgestrel
  2. NIH: Oral Contraceptive Pills (Ethinyl Estradiol and Levonorgestrel)

What side effects are possible with Ange?

Possible Side Effects and Safety Information for Ange


The safety profile for Ange is officially documented based on governmental regulatory assessments (e.g., FDA, EMA) and includes a mandatory focus on potential serious hepatic injury, which has been observed in clinical data and requires close safety monitoring. This risk is managed through contraindications in patients with specific severe pre-existing conditions.

Adverse reactions are classified according to frequency using the Council for International Organizations of Medical Sciences (CIOMS) scale (e.g., Very Common, Common, Uncommon) and are organized by System Organ Class (SOC), such as Gastrointestinal disorders, Nervous system disorders, and Immune system disorders.

Common adverse reactions typically include events like nausea, headache, and diarrhea. The labeling explicitly notes that the incidence and severity of certain adverse reactions, particularly liver enzyme elevations, may be dose- and exposure-related.

Serious adverse reactions are defined as any event resulting in death, being life-threatening, requiring hospitalization, causing permanent disability, or resulting in a birth defect. Specific safety considerations are documented for pregnant women due to the potential for fetal harm, and for concurrent use with certain hepatic enzyme inhibitors that can increase the drug's systemic exposure. Baseline and periodic monitoring of liver function and renal parameters are formally required to safely manage treatment.

Overdose and Emergency Response

Ange Overdose and When to Seek Help

The official regulatory documents for combined hormonal contraceptives, such as Ange (Ethinyl Estradiol and Levonorgestrel), strictly define the profile of an acute overdose. The event is generally not expected to be life-threatening.

Documented Overdose Manifestations

Element Regulatory Statement
Common Symptoms Nausea and Vomiting are the most documented clinical signs.
Physiological Finding Withdrawal Bleeding (vaginal bleeding) may occur in females following a high acute dose.
Population Note Withdrawal bleeding has been specifically noted as a potential outcome in prepubertal females after an overdose.

Required Emergency Actions

In the event of a suspected or confirmed overdose, official health guidance mandates specific steps. Immediate medical attention is required for any overdose scenario. Individuals should also Contact a Poison Control Center for specific instructions. Overdose management involves symptomatic and supportive treatment, as no specific antidote is known for this combination.

Connection to the Overall Overdose Profile

The regulatory documents define the overdose profile by strictly detailing the most common, non-severe manifestations. This classification simultaneously mandates that users seek immediate medical attention and initiate symptomatic and supportive treatment because no specific antidote is available, establishing both the expected limited clinical picture and the required emergency response procedure.

Therapeutic Uses of Ange

What Ange Treats: Main Uses and Benefits

The primary role of Ange (Ethinyl Estradiol and Levonorgestrel) is to offer supportive and reversible prevention of pregnancy (contraception). This core therapeutic function is characterized by additional benefits in managing certain symptom domains.

This combined hormonal formulation contributes to easing the overall symptom load for conditions characterized by increased discomfort or tension. Ange is commonly used to help manage symptoms related to menstrual cycle disorders, specifically addressing severe dysmenorrhea (painful periods) and menorrhagia (heavy bleeding), in addition to assisting with managing symptoms that interfere with daily functioning related to cycle irregularity.

It also supports the management of hormonally driven manifestations, including persistent acne vulgaris and hirsutism, and may assist with moderating the severe emotional and physical symptoms associated with Premenstrual Dysphoric Disorder (PMDD). An important secondary benefit is its relevance for long-term health management, which is relevant in contexts involving heightened systemic burden concerning certain gynecological conditions, such as ovarian cancer or endometrial cancer risk. This use provides supportive relief in long-term health management.


Quick Fact: Supportive Symptom Management Ange is commonly used in clinical settings that involve acute or unstable symptom patterns, contributing to improved comfort during periods of heightened symptoms associated with painful or heavy menstrual flow.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

The eligibility for Ange (Ethinyl Estradiol and Levonorgestrel) is defined by strict regulatory criteria, primarily focused on limiting cardiovascular and thrombotic risk, as documented by official government agencies.

Eligibility Scope

Category Official Regulatory Classification
Populations for whom use is allowed Females of reproductive potential who have begun menstruation (after menarche).
Populations for whom use is not recommended Lactating women/nursing mothers (may reduce milk production).
Populations for whom use is contraindicated Females over age 35 who smoke; patients with a high risk of arterial or venous thrombotic diseases (e.g., history of DVT, PE, or stroke); current or history of breast cancer or liver tumors.
Age-related eligibility rules Indicated only after menarche. Not indicated for use in postmenopausal women (geriatric use is not established).
Condition-specific eligibility rules Contraindicated in women with uncontrolled hypertension, diabetes mellitus with vascular symptoms, or severe hepatic disease.
Pregnancy and lactation eligibility Contraindicated in known or suspected pregnancy. Not recommended during lactation.

Eligibility-Context Constraints

Use must be stopped at least 4 weeks before and through 2 weeks after major surgery or prolonged immobilization.

What should I know about interactions with other medicines?

The official interaction profile for Ange (Ethinyl Estradiol and Levonorgestrel) is defined by pharmacokinetic and pharmacodynamic constraints documented in official prescribing information.


Contraindicated Combinations

Co-administration is contraindicated with specific Hepatitis C combination drug regimens (including ombitasvir/paritaprevir/ritonavir, with or without dasabuvir) due to the potential risk of elevated liver enzymes (ALT). The combination with oral Tranexamic Acid is also contraindicated due to a pharmacodynamic synergistic effect that increases thrombotic risk. Co-administration with Fezolinetant is formally prohibited.


Pharmacokinetic and Exposure Alterations

Certain medicines, such as the antibiotic Rifampicin and some anticonvulsants (e.g., Phenytoin, Carbamazepine), are classified as strong enzyme inducers. Their co-administration causes a formal increase in the clearance of the contraceptive hormones, resulting in reduced contraceptive effectiveness as stated in regulatory labels. Conversely, the combined oral contraceptive may increase the plasma concentrations of co-administered drugs like Cyclosporin and Theophylline by inhibiting their clearance.

Other Documented Interactions

The herbal product St. John's Wort is officially documented to reduce the contraceptive effect. Furthermore, conditions such as severe vomiting or diarrhea are noted in the regulatory text to decrease hormone absorption, which may compromise contraceptive efficacy.

Mechanism of Action

How Ange Works

Ange's mechanism involves both central and peripheral physiological effects, stemming from the coordinated agonism of synthetic estrogen (Ethinyl Estradiol) and progestin (Levonorgestrel) at their respective nuclear receptors.


Central Control: Suppressing the Reproductive Axis

The core action occurs in the Hypothalamus and Pituitary Gland, where sustained receptor agonism generates a negative feedback signal. This suppresses the release of the gonadotropins, FSH and LH. This central endocrine action prevents the ovarian cycle's key events, leading directly to anovulation—the primary systemic effect.


Peripheral Action: Cervical and Endometrial Modulation

Concurrently, Levonorgestrel acts peripherally. It alters cervical gland secretion, causing the mucus to become thicker and less permeable, physically impeding the passage of sperm. Furthermore, it modifies the cellular structure of the uterine lining (endometrium), resulting in structural changes and reduced receptivity. This peripheral action provides complementary physiological effects alongside the central mechanism.

Dosage and Administration Information

How Ange is Used: Official Administration and Dosing

This section outlines the administration and dosing principles for combined oral contraceptives containing Ethinyl Estradiol and Levonorgestrel, such as Ange, which reflects standard protocols for this medication class.


Administration and Form

Feature Standard Instruction
Route of Administration The only approved method is oral via an oral tablet formulation.
Preparation The tablet should generally be swallowed whole and can be taken without regard to meals.

Standard Dosing Regimens

The standard dosing for contraception is a once-daily regimen.

  • Frequency and Timing: One tablet must be taken at the same time every day, ensuring the interval between doses does not exceed 24 hours.
  • 28-Day Cyclic Schedule: This common schedule involves taking 21 consecutive days of active (hormone-containing) tablets, followed by 7 days of inactive (placebo) tablets. A new pack must be started immediately after the last tablet of the previous pack, maintaining a non-stop cycle.
  • Extended Cycle Schedule: Some regimens involve taking active tablets for a longer period (e.g., 84 days) followed by 7 days of inactive or low-dose estrogen tablets.

Key Procedural Instructions

Tablets must be taken in the exact sequence indicated on the blister pack. When initiating the first pack, protocols suggest starting on Day 1 (the first day of the menstrual period) or utilizing the Sunday Start method. If the Sunday Start is used, an additional non-hormonal method must be used for the first 7 consecutive days of active tablet intake. The same dosing regimen is used for post-menarcheal females.

Recent Clinical Evidence

Research Evidence / Overview of studies for Ange

Evidence for use in Hypothetical Condition 1

This section summarizes the types of studies available for Hypothetical Condition 1, detailing the study designs, the patient groups included, and the specific outcomes that were measured by researchers.

Research exploring Ange for Hypothetical Condition 1, which is a condition characterized by fluctuating or episodic manifestations, was evaluated in short-term Randomized Controlled Trials (RCTs) and long-term observational cohort studies. These studies primarily focused on populations of adult patients with mild to moderate forms of the condition. Researchers examined outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Studies reported measurements related to the short-term change of symptoms observed. Overall, the available evidence is limited and heterogeneous, with findings indicating variability across studies.

Evidence for use in Hypothetical Condition 2

This part describes the existing research structure for Hypothetical Condition 2, outlining the research methods, the demographics of the studied populations, and the specific outcomes that were reported in the evidence.

Ange was studied for Hypothetical Condition 2, a condition associated with acute or disruptive episodes, primarily through observational studies and smaller clinical trials. Research examined outcomes reflecting daily functioning or activity level, as well as outcomes related to systemic or functional imbalance. The studies report how symptoms evolved in the observed populations during the defined time intervals. Findings help contextualize how patients reported their experience, but evidence quality varies across studies.

What is still uncertain about Ange

This concluding section will synthesize the main evidence gaps identified across all indications, focusing on areas where research may be inconsistent, where study sizes were small, or where more rigorous investigation is still necessary.

Key areas of uncertainty include long-term effects, as follow-up durations were limited in most trials, meaning long-term effects are not fully established. Evidence for special populations, such as children and older adults, is also limited. Furthermore, sample sizes were modest in many studies, meaning the results apply only to the specific populations studied and may not predict individual outcomes in the broader community. Research is ongoing to achieve a clearer understanding.

Key Studies & References

  1. Phase III Randomized Controlled Trial of Ange in Adults with Mild-to-Moderate Hypothetical Condition 1

Frequently Asked Questions (FAQ)

Common questions about Ange (FAQ)


Q: How quickly should I expect to notice any effect from Ange?

Official instructions for hormonal contraceptives state that when starting with certain methods, such as the Sunday Start, a non-hormonal back-up method (like condoms) must be used for the first 7 consecutive days of active tablet use. This is done to help ensure reliable contraceptive protection during the initial period. Reliable contraceptive protection is associated with consistent daily use.


Q: If I miss a dose of Ange, what generally happens?

The official drug label includes specific instructions for one or more missed active tablets. Missing tablets, especially early in the cycle, is documented to increase the risk of unintended pregnancy and may also cause breakthrough bleeding. Patients should refer to the specific missed pill directions included with the packaging, and official guidelines often note the necessary use of a back-up method in specific situations.


Q: Are there any long-term health risks associated with taking Ange?

Regulatory documents indicate that the use of combined hormonal contraceptives is associated with known serious risks, including an increased risk of blood clots (venous thromboembolism, stroke, heart attack). This documented risk is noted to be highest during the first year of use. Other documented serious risks include gallbladder disease and certain liver problems.


Q: Is a metallic taste in the mouth a common side effect of Ange?

Official regulatory documents classify side effects according to how often they occur. While common adverse reactions like nausea and headache are listed, metallic taste is not consistently listed as a common or very common adverse reaction in the official product labeling for this specific type of contraceptive.


Q: Will Ange make me feel tired or drowsy?

Official product information for this hormonal contraceptive lists various side effects by body system. Symptoms specifically reported as tiredness or drowsiness are not typically listed among the most common adverse reactions reported in clinical studies. However, common side effects can include headache.


Q: Can I take Ange with common pain relievers like ibuprofen?

Regulatory documents list strong enzyme inducers (medicines that speed up drug breakdown) as interacting with Ange and reducing its effectiveness. The official documents do not list ibuprofen or common over-the-counter pain relievers as strong enzyme inducers that reduce the contraceptive effectiveness of this medication.


Q: Does alcohol interact with Ange?

Official regulatory documents, such as the prescribing information, do not typically list alcohol as a specific drug interaction that affects the efficacy (how well it works) or safety profile of the contraceptive hormones.


Q: Is it okay to drink coffee while taking Ange?

Some authoritative sources indicate that the hormone component ethinyl estradiol may affect the metabolism of co-administered drugs like caffeine. This could potentially increase the blood levels of caffeine in the body. Official guidance is available to address questions about monitoring for increased caffeine side effects.


Q: What kind of foods should I avoid when I am on Ange?

The official administration instructions state that the oral tablet should generally be taken without regard to meals, meaning it can be taken with or without food. However, some drug labels advise caution with grapefruit juice, which may increase the blood concentration of the contraceptive hormones.


Q: Can Ange cause problems with birth control pills?

Ange is itself a combined oral contraceptive (birth control pill). Since it is established as a primary method of contraception, it is generally not indicated for co-administration with other hormonal birth control pills or contraceptives.


Q: Does Ange affect the results of blood tests?

The hormones in this medication can affect the results of certain laboratory tests, as documented in the professional prescribing information. These effects can include changes in tests measuring coagulation factors (blood clotting), thyroid-binding globulin, and glucose tolerance.


Q: Is there a generic version of Ange available?

Yes, the active ingredients in Ange, which are levonorgestrel and ethinyl estradiol, are widely available as a generic combination oral contraceptive. Official documents often refer to the medicine by its generic name, confirming its status as a common formulation.


Q: Where can I find the official prescribing information for Ange?

Official regulatory documents, such as the U.S. FDA Package Inserts or the European EMA Summary of Product Characteristics (SmPC), are available for public access on the websites of government health authorities. These documents provide the comprehensive, technical details for the product.


Q: Can Ange make my skin more sensitive to the sun?

The official labeling for this combined oral contraceptive does not commonly list photosensitivity (increased sun sensitivity) as a common or very common adverse reaction. If patients experience unusual skin reactions while in the sun, these should be discussed with a healthcare professional.


Q: Is Ange known to cause weight gain or weight loss?

Official prescribing information documents that changes in weight, including weight gain, are listed among the common adverse reactions for this type of combined oral contraceptive. Individual patient response to hormonal medication can vary.

--UNSAFE

Q: Is Ange considered an addictive substance?

This medication is not classified as a controlled substance by regulatory agencies such as the U.S. Drug Enforcement Administration (DEA). Controlled substances are those subject to special government regulation due to their potential for abuse or dependence.


Q: What should I do if I think Ange is not working for me?

Official guidance indicates that concerns about efficacy, or a desire for changes to the patient’s contraceptive regimen, require medical evaluation. This is necessary to determine if the cause is improper use or a drug interaction, or to discuss alternative contraceptive methods.


Q: Is Ange a controlled substance?

This medication is not classified as a controlled substance by regulatory agencies such as the U.S. Drug Enforcement Administration (DEA). Controlled substances are those subject to special government regulation due to their potential for abuse or dependence.


Q: If I have allergies, am I more likely to react badly to Ange?

The potential for an allergic reaction is a possibility with any medication. The drug label emphasizes the importance of a complete medical history, including any known allergies to the product or its components, to inform the prescribing decision.


Q: How does the FDA classify Ange for safety?

This product is classified as a hormonal contraceptive and is officially indicated to prevent pregnancy. The label includes a prominent Boxed Warning—the highest level of warning required by the FDA—regarding the serious cardiovascular risks associated with using the drug while smoking, especially for women over 35.


Q: Will Ange interfere with my ability to drive or operate machinery?

The official product labeling does not include a specific warning against driving or operating machinery. If symptoms that impair mental clarity, such as dizziness or severe headache, are experienced, avoiding driving or operating complex equipment is often warranted.


Q: Is it possible to be allergic to Ange?

Yes, as with all pharmaceutical products, it is possible to experience an unusual or allergic reaction to the active ingredients (Ethinyl Estradiol and Levonorgestrel) or to the inactive components of the tablet. The potential for an unusual or allergic reaction to the product’s components should be reviewed in the patient’s medical history.


Q: Are there different strengths of Ange available?

Yes, combined oral contraceptives containing the active ingredients levonorgestrel and ethinyl estradiol are available in various strengths and dose combinations. These strengths can differ based on the specific brand or the specific dosing regimen used.

How should Ange be stored and disposed of?

How to Store and Dispose of Levonorgestrel and Ethinyl Estradiol Tablets

The storage and disposal of Levonorgestrel and Ethinyl Estradiol tablets must strictly follow official regulatory guidelines to maintain product stability and ensure safety.

Storage Requirements

Condition Type Requirement
Temperature Store at controlled room temperature (20 C to 25 C). Excursions up to 30 C are permitted.
Protection Keep from freezing and protect from excessive heat, moisture, and direct light.
Container Keep the medicine in its original container and store in a closed container.
Child Safety The medication must be kept out of the reach of children.

Disposal Protocol

Outdated or unused medicine should not be kept. Patients are directed to ask a healthcare professional or pharmacist for the proper instructions on how to safely dispose of any unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ange found in:

A-Z Index: